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Introduction
We proposed to develop and evaluate a novel therap eutic approach to breast cancer, which m ay be effective at any stage o f tum or developm ent, but whic h would be m ost relevant to advanced dissem inated disease. We will combine a novel tumor vascular target with new radioarsenic chemistry to generate a platform technology encompassing tumor detection, dosimetry, and radio immunotherapy (RIT). Recently, Thorpe et al.
identified phosphatidylserine (PS) as a new vascular target and generated an antibody (3G4) (1) (2) (3) . It is thought that PS is exposed on tum or vasculature due to stress c onditions in the tum or microenvironment. Externalized PS is a desirable m arker for tumor targeting for several reasons: 1) PS is specifica lly and abundantly expressed on tumor vascular endothelium; 2) it is present on a high percentage of tumor endothelial cells in various solid tumors; 3) it is absent from normal vessels; 4) it is on th e luminal side of tum or endothelium, which is readily accessible for targeting drugs. Since this target should be ubiquitous among tumors, we believe PS can form the foundation for a potent new anti breas t cancer therapy. 3G4 has been de veloped as Tarvacin (a human chimerized monoclonal antibody, which has recently been given the USAN na me bavituximab) by Peregrine Pharmaceuticals, who now have an IND to initiate Phase 1 clinical trials based on direct the rapeutic efficacy (4) . However, at m uch lower doses, we believ e Tarvacin may be used to detect breast tum ors using positron emission tomography (PET) and treat them by radio immunotherapy base d on arsenic radi onuclide ligands.
Such system ic therapy should effectively target disse minated disease, yet provi de highly localized tumor specific toxicity.
To efficiently apply bav ituximab to breast canc er, we will use radioisotopes of arsenic. Multiple isotopes are av ailable with d iverse ch aracteristics m aking them suitab le f or n uclear m edicine im aging and radio immunotherapy. Arsenic-74 has a lo ng half-life (~18 days) and positron em itting activity making it suitable for PET in anim al models, while 72 As would be su itable in the clinic (5-7). Meanwhile, 77 As is a pure β -emitter, potentially suitable for radio imm unotherapy (RIT). Jennewein and Rösch (consultants) have developed novel chemistry to effectively isolate arsenic radionuclides from irradiated germanium targets and generate ligands of radio a rsenic on antibo dies to targ et brea st tu mors. To date dosim etry has been a m ajor obstacle to effective RIT, since the pharm acokinetics and accumulation in tumors of m Abs can be high ly variable. We believ e we can establish a novel approach for tum or detection (both primary and metastases), w hich will allow analogous chemistry for targeted radio immunotherapy.
It should be noted that the antibody Tarvacin has now been formally named bavituximab.
Body and Progress
Phase 1 Optimize Tarvacin labeling with arsenic radionuclides for imaging, biodistribution, and radio immunotherapy. with Pereg rine Pharmaceuticals) will be deri vatized with N-succin imidyl S-acetylthioacetate (SATA), label ed with the radionuclide 77 As, and evaluated for activity.
Arsenic-77 is a 100% β -e mitter which could be a possible new candidate in rad ionuclide th erapy, e.g., intravascular radiation therapy (IVRT), or radio-immunotherapy (RIT). This radionuclide can be produced from natural germanium in nuclear reactors through the neutron induced nuclear reaction, 76 Ge (n, γ) 77Ge , where 77 Ge decays to 77 As with a half life of 11.3 h. Dr. Sun negotiated supplies of 77 As from the nuclear reactor facility at the University of Missouri (MURR) courtesy of Dr. Ca thy Cutler. During years 2 and 3 our radiochem ist, Dr.
Guiyang Hao has continued developm ent of radiochem istry. 77 As-Bavi
Free 77 As o 1, although 10 to 1 gave poorer result that 5 to 1. Using less Na 2 SO 3 gave better yields as ce copper has isot opes suitable for both P ET and radio as proposed in our project for 74 As (or 72 As) and 77 As. Initial data look very pro The preparation of the DOTA-Bavi hod. In order to remove the sm all molecules and dimm ers, the conjugate was purified by HP LC with size exclusion column. The fractions were collected and concentrated for radiolabeling.
Radiolabeling of Bavituxima
64 Cu-DOTA-Bavituximab was labe led in 50 -60% labeling yields and 98% radioc hemical purity after BioSpin column purification. The labeling yields can be in creased to more than 95%, if more DOTA-Bavituxim ab is added into 64 Cu solution.
Biodistribution of 64 Cu-DOTA-Bavituximab: It was shown in Fig. 9 that Cu-DOTA-Bavituximab had hi gh
The uptake in liver, kidney, and other normal tissues except spleen w as 64 tumor uptake (6.6 %ID/g) at 24 hr p.i. Center #1 at 24 hr p.i.
Bottom mouse #2 at 24 hr p.i.
Task 2
Months 5-6 Tarvacin derivatization with 74 As. We anticipate that the chemistry of any arsenic radionuclide will be identical. 77 As will also be the isotope of choice for rad io im munotherapy in Phase 3.
Imaging based on Positron Em ission Tomography (PET) will require Department of Energy. Unfortunately, th e laboratory finally inform ed us in Decem ber '08 that they would not after all be able to ship us any 74-As. We will therefore return to the original plan of obtaining shipments from Europe. Dr. Herm anne from Brussels has confirm ed his willingness to provide 74 -As, as per attached letter.
While frustrating, the delay is not entirely disadvantageous, since UT Southwestern has made major advances in radiochemistry facilities and P ET/CT during 2008. W e are now far be tter equipped to undertake the radiolabeling and tomographic imaging. In fall 2008 a new Siemens Inveon PET/CT instrument arrived and was commissioned. Dr Sun also occupied new state of the art radiochemistry labs, which we believe we will grea tly accelerate our research and achieve the original goals during the requested 1 year no-additional cost extension.
Phase 2
Detection of diverse primary breast tumors and evaluation of metastatic spread using radio arsenic labeled Tarvacin.
Task 3 Months 7-12 Determine ability to detect human breast tumor xenografts in nude mice.
MDA-MB-231-Luc (luciferase expressing) and MDA-MB-435-Luc cells will be implanted in mammary fat pad (MFP) of mice and a llowed to grow. Growth will be monitored using calipe rs an d biolum inescence im aging (BLI). When tumors reach 0.5 cm diameter 74 As-SATA-Tarvacin (100 μCi) will be adm inistered IV to half the mice and distribution of agent will be assessed every 12 h using planar γ-scintigraphy. After 60 h sm all animal PET will be used to quantify biodistribution in vivo. At this stage, the d osed mice will be sacrificed to a ssess biodistribution ex vivo. The rem aining animals will b e further monitored by BLI a nd are expected to dev elop lung metastases, which will b e visualized by B LI. Once m etastatic spread is appare nt (typically, when prim ary tumors reach ~ 1 cc) 74 As-SATA-Tarvacin will again be adm inistered to assess the ability to de tect metastases using PET. Following P ET, mice will be sa crificed to d etermine biodistribution ex vivo and ex amine extent of metastases histolog ically. W e will also label Rituxim ab, a comm ercial non-v ascular targeting chim eric antibody, as a control (12 tumors x 2 tumor types x 2 different antibodies = 48 nude mice)
We have generated and tested highly expressing MDA-MB-231-Luc tumor cells, which will be required for the radio tracing studies and PET. Report approved previously.
Task 5 Months 13-15 Determine ability to detect breast cancer in a bone metastasis model.
Bone metastases will be induced by i ntra cardiac injec tion of MDA-MB-231 and -435 luciferase expressing cells.
Should this fail, we will implant cells directly in the femur of nude mice. Tumors will be allowed to grow and BLI will be performed twice weekly. Once BLI shows evidence for tumor growth as models of metastasis, 74 As-SATA-Tarvacin will be administered IV, as for Task 3 and t he ability to detect the tu mors will be assessed using γ-scintigraphy and PET. As-SATA-Tarvacin will be adm inistered IV and biodistribution assessed in vivo using PET after 24 and 60 h. Rats wi ll then be sacrificed for ex vivo biodistribution and pat hological examination of metastases expected in the lungs and lymph nodes, respectively. Separate cohorts of rats will be examined when primary tumors reach 1.5 and 2 cm diameter at which time metastases are expected. (6 tumors x 2 tumor types x 3 sizes = 36 rats).
Prior to extensive radionuclid e imaging of rats we have conducted initial tests for proof of principle. W e have examined biodistribution of 77 As -bavituximab in control non-tum or bearing rats. Rats survived administration and biodistribution of antibody was feasible. Thorpe has previously shown that PS is exposed in essentially every tum or type investigated (2). Prior to nuclear imaging studies we tested for exposure of PF in rat breast tumor ( Figure 13 ). The panels show section of 13762NF syngeneic rat breast tumor form a Fisher rat. Bavituximab or C44 were infused into tumor bearing rats and tumors excised 24 h later. P rior to excision anesthetized rats were perfused with saline to remove unbound antibody. Panels a and d show tum or vasculature based on CD31-staining. Panels b and e show retention of antibody. B shows extensive bavituxim ab uptake, which is seen to be asso ciated with blood vessel in the overlay image c. C44 was not detect. C and f show overlays and inclusion of DAPI staining for nuclei.
As-77-SATA-Bavituximab in Normal Rats
Frozen sections were prepared and fixed with acetone. Mouse anti-rat CD31 and biotin labeled goat anti-human antibodies were used and followed by cy2 labeled streptavidin and cy3 labeled goat anti-mouse Report provided last year.
Phase 3
Evaluate Tarvacin based radio immunotherapy of breast tumors.
Task 8 Months 25-30
Assess response to single dose RIT using Investigations to be undertaken duding proposed no-cost extension. ii) infuse single dose 77 As-SATA-Tarvacin as for Task 8, followed by non radioactive T arvacin at therapeutic dose (100 μg/kg) twice weekly for three weeks.
iii) infuse Tarvacin Investigations to be undertaken duding proposed no-cost extension.
Task 10 Months 34-36 Prepare manuscripts and final report.
3 rd year report provided here in place of final report, since request has been submitted for no-coat extension.
KEY RESEARCH ACCOMPLISHMENTS:
• Improved yield of isolated 77 AS
• Opened new state of the art radiochem istry laboratories with additional fum e hoods, lead shielding and adjacent animals housing.
• Commissioned new commercial PET/CT: Siemens Inveon PET/CT Multimodality System 
CONCLUSION:
We have verified the ability to generate and isolate 77 As based on activ ation of germanium oxide in a nuclear reactor. The current yield is lower than antici pated and we are exam ining m ethods of increasing the yield. We secured a ne w supply from MURR, which is able to generate m uch higher doses of 77 AS. We have demonstrated the ability of bavituximab (Tarvacin) to localize in rat breast tumor, as detected by immuno histochemistry, which is a crucial foundation for in vivo studies in rats. T hese new results provide a foundation indicating that the project will be successful.
We have requested a 1 -year no-ad ditional cost extension. There were several reas ons for delays in the investigations: i) we had hoped to ob tained supplies of the arsenic-74 from the Los Alamos National Labs. apologize for the delay in getting back to you. I am debating with LANL when we can start producing As-74. I propose to do a test irradiation in July, send you the target to confirm that the quality of the product is acceptable. The cost estimate is about per target.
I foresee you submitting a proposal that outlines the demand for As-74 for your research in response to future solicitations.
I will be in South Korea next week. I will get back to you on this topic the following week to hopefully come to an agreement.
Please could you send an e-mail to the Isotope Business Office (clinerl@ornl.gov) requesting As-74. That way your request becomes an official track number. I regret to inform you that we will not be able to irradiate and ship a target to you from LANL in 2008. We were unable to find a suitable shipping container for the target that met both of our needs before the beam to the accelerator (and our irradiation capability) goes down this weekend. We will not have irradiation capability again at LANL until ~June of 2009.
Regards
I apologize that we were unable to find a suitable container and that I was not able to give you a firm answer back in June when we first discussed this. When it was determined that your facilities did not have the necessary infrastructure to use our approved shipping container, I had hopes that we would be able to identify an alternative container, but after evaluating several containers from June through December, we still could not find a container that would work for both of us. When I learned in December that our shippers were hesitant to use the latest container we thought might work, I knew there would not be time to finalize the container before we lost our opportunity to irradiate. If something changes between now and June of 2009, I will let you know. Dear Sir,
We are honoured to receive your request for a quotation for the production of As. The changes for the irradiation will be as follows.
Production of ± 37 GBq of 74 As by nat Ge(α,x) 74 As reaction. Estimated beam time 1 hour at 15μΑ on target, Ep= 20 MeV; cost : 900Eur A handling and measuring fee of 120Eur will be added. These costs are 12% overhead and 21% VAT not included. These taxes will have to be added if an official invoice form the Vrije Universiteit Brussels is needed, but can be avoided if a simple bill for reimbursement issued by our lab is sufficient. Payment should then be be done by transfer to a bank account of the VUB Cyclotron c/o A. HERMANNE.
The price does not include transport or shipment, which should be organised on mutual agreement and paid separately. The price for one package , a type A UN2915 cardboard box containing a Pb shielding container, would be about 600 Eur, taxes and fees not included. The colli, not to be returned, will be provided by us and are estimated at 100-120Eur a piece. In the hope that this quotation can meet your approval and awaiting an official order stating number of irradiations wanted and optimal date of delivery.
Best regards
Prof. A. Hermanne Head of Cyclotron Department.
Submitted Applied Radiation Isotopes
Separation and purification of no carrier added arsenic from bulk amounts of germanium being adequate to radiopharmaceutical labeling chemistry 
Introduction
Arsenic:
The ele ment arsen ic is well known as the f avorite po ison of the Savell is, th e Borgias and Agatha Christie [1] . Th ere were also speculation s th at N apoleon Bonaparte d ied b ecause of arsenic poisoning [2] . Because arsenic is viewed as sy nonymous with toxicity it is still used today for homicides or suici des [3] . A wor ldwide problem is the lo cal high po llution of natural wat er with arsenic und er natur al conditions or as a resul t of addition al human pollution [4] . Therefore the removal of arsenic from drinking water is an important challenge. Despite its toxi c properti es arsenic was us ed 2000 y ears ago by Greek and Ch inese healers as therapeutic agent to treat everything from syphilis to cancer [1] . More recently, the use of arsenic trioxide (ATO) in European medicine increased after the invention of Fowler's solution which was used for a number of systemic illnesses from 18 th to 20 th century. Over the last 1 00 years, the concerns about toxici ty and pot ential carcinogenicity o f arsenic administration have declined its use for medical application [5] . At the end of the last century it w as found th at ATO has v ery go od t herapeutic characteristics fo r t reatment of ac ute promyelocytic leukemia (APL) and c linical trials have been confir med all around the world [6, 7] . Some years ago ATO was approved by the U.S. Food and Drug Administration (FDA) as Trisenox ® for this indication [8] .
Another app lication of arsenic radioisotopes might be its use as radio active probe in sub-toxic t race a mounts for biol ogical or medical purposes. The tra cer concept of radiopharmaceutical ch emistry a llows the app lication of no ca rrier added (n ca) a mounts of radioactive isotopes (e.g. of arsenic) that are used for labeling of interesting biological carriers like monoclonal antibodies (mab) and the i maging of their biological b ehavior in vivo. Th e element arsenic provides a range of isotopes for non-invasive PET imaging like 72 As (T 1/2 =26 h; 88% β + ), and 74 As (T 1/2 =17.8 d; 29% β + ). These isotopes are produced by (p,n)-reactions on natural or isotopically enriched targets of metallic germanium or germanium(IV)oxide and are therefore av ailable in n ca stat e. Additionally, th e β -e mitter 77 As (T 1/2 = 38.8 h; 100 % β -) i s produced by bombardment of the same target materials with neutrons, followed by β -decay of 77 Ge (T 1/2 =11.3 h; 100% β -).
Separations
Various methods for the separation of germanium and arsen ic have b een reported so far. A collection of separating procedures for germanium and arsenic from fission products is given elsewhere [9] [10] [11] . The ma jority of these methods is b ased on distillat ion of germanium as GeCl 4 fol lowed by distillation of arsenic as As Cl 3 . Other m ethods w ere based on sol vent extraction o r precipitation [12] of one of the two el ements. Most of these methods fail for radiopharmaceutical app lication because arsenic carrier w as use d, which is not in common with the t racer concept. A review on the ch emical behavior of radio germanium is given by Mirzadeh et a l. [13] , involving separation techniques for radioarsenic. Separation of As(III) from antimony a nd bismuth was achieved in 8 M HCl a nd extraction into b enzene [14 ] . A systematic study on separation of As(III) and Ge(IV) in H Cl and HI systems by liquid liquid extraction into several solven ts was carried ou t by Brink et al. [15 ] . A n easy sep aration of arsenic from germanium was a chieved by solvent extraction of arsenic fro m sulf uric ac id solutions after addition of KI into toluen e [16, 17] . Another strategy for the sep aration of As from GeO 2 in HCl is the ox idation of As to As(V) and ext raction o f the G e into org anic solvents [18] [19] [20] . After the separation the As(V) is reduced again to As(III) and extracted into organic solvents. Tolmachev et al. [21] processed a germanium(IV)dioxide target after proton bombardment by dry distillation foll owed by w et ch emistry wo rkup for additi onal purification. The low target l oss of less t han 1 % was mentioned as f ar as a furt her target recovery is not ne eded. S ome methods based on d istillation of GeCl 4 are r eported whereas arsenic w as kept in the nonvo latile f orm of As(V) [22] followed by solvent ex traction [23, 24] , cation exchange [25] or anion exchange [26] . Schindewolf et al. [27] absorbed Ge and Ga from diluted HF so lutions on anion exchange resin AG 1X8 while As(III) was not a bsorbed. Some more data about the behavior of As(V) in HF media [28] and mixtures of HF/HNO 3 media [29] on AG1X8 is available although data for Ga differ in [27] and [28] . The behavior of Ge, As(III) and As(V) in HCl media on AG1X8 is very well known from literature [30] [31] [32] and some data about the absorption in HCl/acetone media is available [33] . Ge and As(III) are strongly absorbed at h igh HCl concentrations and ca n easily be se parated from As(V) which shows only slight absorption. Korkisch et al. [3 4 ] used the sa me r esin, but HCl/a cetic acid medium for separation of Ge and As(III)/As(V). Arsenic behavior on cation exchange resin is determined by very low abs orption coefficients in H Cl a nd HClO 4 m edia [35] . A slightly higher absorption was found in HCl/acetone media [36] and in HBr media [37] . Jennewein et al. [38] developed a separation method for GeO 2 targets based on solid phase ex traction after dissolving the target in HF conc . The radioarsenic was fixed on a BOND ELUT ENV cartridge after treatment with NaI while the GeF 6 2-formed in HF passed without interaction through the column. After drying the cartridge with nitrogen gas the radioarsenic was eluted with ethanol. This method so far is the only one that lead to a radioarsenic labeled mab [39] that was used for tumor imaging with PET in vivo [40] . There are al so so me in teresting app roaches that are far-out the nor mal standard te chniques. Maki et al. [41] developed a separation technique for 
Targetry
Preliminary tests for the production of radioarsenic isotop es on GeO 2 -targets at high flux reactors and cyclotrons showed for long term irradiations of 1 week (reactors) or high proton beam currents (more than 2 µA) that, following di ssolution in HF conc , appreciable amounts of the ta rget ma terial formed ins oluble co mpounds as a consequence of thermal stress and radiolysis. This i nsoluble co mpound was identified as ele mental germanium. H owever, aiming for m edical application of radioarsenic isotop es, high neutron fluxes or high proton beam currents n eed t o be applied on the targets for high production yields. Therefore germanium metal of natural composition was chosen as target material.
Approach
The aim of this w ork thus was to set up a p rocedure fo r sepa ration of nca amounts of radioactive arsenic isotopes from macroscopic amounts (100 -200 mg) of irradiated metallic germanium. The d esired high purity of the fin al radioarsenic fraction was intended by crude separation of ger manium by dist illation o f G eCl 4 followed b y anion exchange chromatography to remove the rem aining trace am ounts of ge rmanium. Additionally, a separation of radioactiv e con taminations (gal lium and zinc isotop es form ed during neutron bombardment [43] , namely 72/73 Ga and 69m Zn) was considered. In cy clotron irradiations, the major contam ination fo und was 67 Ga. The separati on of those con taminations is very important as fa r as a radioarsenic based tracer for possi ble human us e must b e available in highest rad iochemical purity. The co mbination of a dis tillation technique wit h an anion exchange co lumn has b een used in a si milar s etup before [26] . Th is method lead t o a h igh purity *As(V) fraction in 10 M HCl not feasible for labeli ng of biomolecules. The challenge for the labeling of mab is first to reduce the *As(V) to *As(III) and second to remove the 10 M HCl as far as mab labeling requires a pH of around 7. For a spired in vivo experiments the final product needs to be concentrated to low volumes of about 500 µl or less.
Materials / Methods

Materials
If the radioarsenic is used for labeling chemistry of proteins in nanomolar concentrations care must be taken that the addition of cold arsenic carrier by used chemicals is minimized. This is also the case as long as the radiolabeled product sh all b e used in a clinical e nvironment. Therefore all chemicals were purchased in the highest purity available, e.g. suprapure acids. Germanium m etal (99.999%) was purchased from Goodfellow as a plate of 50x50x0.5 mm and laser-cut into discs of 9.9 mm diameter (204 mg each) and used for cyclotron irradiations. For reactor irradiations, germanium metal (99.9999%) was purchased from Chempur in small pieces rang ing fro m 1 00 -200 mg. Con centrated nitric acid (65 %, Su prapur) and hydrochloric acid (30 %, Su prapur) w ere purchased fr om VWR. CuCl (9 9.995+%) and chloroform (analytical grade) were purchased fro m Sig ma Aldrich. A nion ex change resin AG1X8 (200 -400 mesh) was p urchased fro m BioRa d. PBS buffe r and TCE P (tri s(2-carboxyethyl)phosphine) were purchased from Pierce.
Proteins
The monoclonal antibody Bevacizumab was chosen as a model protein for the demonstration of t he ab ility of t his method t o provide radioarsenic in a form suitable for l abeling of SH group bearing molecules. The Bev acizumab was purchased from LaRoche at a concentration of 25 mg/ml. Bevacizumab is d irected ag ainst the VEGF receptor an d used as a nti can cer agent in hu man therapy [44, 45] . Each la beling exper iment w as p erformed b y using 50 µl (corresponding to 1.25 mg) of the original antibody solution. The solution was fil led up with 450 µl of PBS buffer and added to the radioarsenic solution.
Irradiations
The positron emitters [38, 47, 48] . For the production of positron e mitting arsenic isotopes ( 72 As and 74 As) germanium discs of 9.9 mm diameter and 0.5 mm thickness (204 mg) were placed into an alu minum container and cov ered with a 50 µ m Harvard foil. The beam current was u p to 30 µA with 15 MeV protons and irradiation time was diversified from 0.5 to 5 h. In tegrated loading was up to 100 µA h. This set up showed no destructi on of target material. As far as Ge ta rgets of n atural composition were used 70, 71, 72, 73, 74, 76 As are produced v ia (p,n) reactions. Major isotop e after 1d cooling t ime is 72 As. If t he target was allowed to cool for 1 week the major isotope is 74 As with small contaminations of 71/73 As. In a cyclotron irradiated target any Ge isotopes formed are not useful for γ-ray spectroscopy due to undesirable low cross sections. The system 77 Ge/ 77 As provides a uniqu e option for detec tion of both elements simultaneously. The nca isotope 77 As (T 1/2 = 38.8 h; 100% β -) was produced by ( n,γ)-reaction on nat Ge targ et in a nuc lear r eactor. It w as used for optimization of the chemical separati on pro cedure, determination of y ields and for the optimization of labeling chemistry. Detaile d cross se ctions for nuclea r reactions of neu trons on ger manium can b e found elsewhere [43 ] . The production of 77 As was carried out by irradiation of 100 -200 mg germanium metal pieces for 6 h at a neutron flux of 4.2•10 12 n cm -2 s -1 at the TRIGA Mark II reactor of the Institute of Nuclear Chemistry, Mainz. The target was allowed to cool for 18 h to for m 77 As from dec ay o f 77 Ge and used directly for sepa ration. Therefore th e separation factors ha ve been measured i n th is system and the sa me procedure was the n applied to the positron emitting, cyclotron produced arsenic isotopes.
Radiochemical separation
Dissolving the target: The germanium target (100-200 mg) was placed in a quartz distillation apparatus ( Fig. 1 ) and 4 ml aqua regia was added. The apparatus was heated to 120°C and during this time the irradiated germanium metal dissolved. 4 : After complete dissolution of the target the temperature was maintained at 120°C for distillation of G eCl 4 . For accelerati on of th is pro cess a s tream of A rgon w as bubbled through the solution. O ver a p eriod of 1.5 h additional 6 ml of HCl (10 M) were added. The GeCl 4 was t rapped in an ice c ooled v essel containing 20 % H 2 SO 4 . After completed clearance the solution was condensed to less than 500 µl.
Distillation of GeCl
Anion exchange: The distillation solution was filled t o 500 µl with 10 M HCl. The solution was transferred onto an anion exchange column (3*100 mm, AG1X8) i n the chlo ride for m and eluted with 500 µl fractions of 10 M HCl. Arsenic *As(V) was eluted in the fractions 2 and 3. Aft er 10 fractions the elu ent w as switched to 0.1 M HCl for re moval of galliu m, germanium and zinc isotopes.
Reduction of As(V) to As(III), extraction into CCl 4 and back extraction into PBS-buffer:
Fractions 2 and 3 were combined (1 ml solution) and mixed with 50 mg CuCl. Th e mixture was heated at 60°C for differe nt p eriods ranging from 5 to 120 minutes, with 60 minutes finally applied for the batch experiments. The As(III) was ext racted twice with 500 µl CCl 4 . Combined CCl 4 fractions we re e xtracted with 500 µl PBS-buffer containing 25 mM EDTA and 0.5 M hydroxylamine.
Speciation of As(III) and As(V):
The oxidation s tate of the radioarsenic in the CCl 4 an d the PBS frac tion was deter mined by ra dio TLC. 0. 5 µl of eac h fraction w as spotted on a Si-60 silca plate and dev eloped w ith 0 .01 M sodiu m tartrate / methanol 3 : 1. TLC p lates wer e analyzed using an Instant Imager from Packard.
Determination of radiochemical purity and radiochemical separation yields:
The radiochemical p urity and separation yield were deter mined b y γ-ray spectr oscopy. Th e activity of t he und issolved Ge target and of 500 µl aliquots of th e s olution after each step were measured in th e s ame g eometry and co mpared qu antitatively. The γ-ray spect roscopy was performed using an Ortec HPGe detector system and Canberra Genie 2000 software. For the 77 Ge/ 77 As-system, the two nuclides were determined by their most abundant γ-lines of 239 keV (1.6 % ) for 77 As a nd 264 keV (53.9 %) for 77
Ge. As long a s 77 Ge has a much higher gamma e mission rate compared to 77 As it is clea rly visible in t he target spectru m but c ould not be detec ted in the purified frac tion. Care was ta ken that the d ead time of th e detector remained always be low 10 %. The irra diated ta rget wa s measured in 1 m distance t o th e detector for 15 min, wherea s t he purified fraction was m easured fo r 12 h directly on the surface of the detector. All data were normalized to th e time point of the first acquisition by the acquisition software. 
Fractions [500 µl] eluted activity [%]
As-77
Ga-72
Zn-69m As(V) distillate for reactor irradiated Ge target. As(V) is eluted in fraction 2 and 3 in 10 M HCl. Eluent was changed to 0.1 M HCl in fracti on 11. U nder these conditions Ga and Zn isotopes are eluted from the column. As-Avastin after 1 h (black: UV 280 nm, blue: radiosignal)
